Immunocore, a biotech firm located at 2273 Research Boulevard in Rockville, has won a prestigious Prix Galien France award. It received the honor for its breakthrough therapeutic, KIMMTRAK, the world's first T cell receptor therapy. Immunocore took home that award in the "Medicine in Innovative Therapeutics" category. KIMMTRAK is the only therapy approved for the treatment of unresectable or metastatic uveal melanoma, and the first bispecific T cell engager to receive regulatory approval to treat a solid tumor.
“We are honored to receive this prestigious award, which is a reflection of the impact of this novel treatment for patients and the innovative technology behind it,” Immunocore CEO Bahija Jallal said in a statement. “This award is also a tribute to the teams at Immunocore who have taken KIMMTRAK from bench to bedside, and those working on our future therapies that could benefit more patients living with cancer, as well as infectious diseases and autoimmune conditions.” KIMMTRAK received FDA approval this past January. Immunocore's press release notes that the Prix Galien France awards are considered the equivalent of the Nobel Prize in the biopharmaceutical research field.
Photo courtesy Immunocore
CONGRATULATIONS! And keep the good work up🙏
ReplyDelete